إعلان
إعلان

ITRM

ITRM logo

Iterum Therapeutics plc Ordinary Share

0.36
USD
برعاية
+0.01
+2.80%
٠٧ يناير, ١٥:٥٨ UTC -5
مغلق
exchange

بعد الإغلاق

0.37

+0.01
+2.50%

تقارير أرباح ITRM

النسبة الإيجابية المفاجئة

ITRM تفوق 17 من 29 آخر التقديرات.

59%

التقرير التالي

بيانات التقرير القادم
٠٥ فبراير ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$3.07M
/
-$0.09
التغير الضمني من Q3 25 (Revenue/ EPS)
+685.92%
/
-55.00%
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/
-60.87%

Iterum Therapeutics plc Ordinary Share earnings per share and revenue

On ١٤ نوفمبر ٢٠٢٥, ITRM reported earnings of -0.20 USD per share (EPS) for Q3 25, missing the estimate of -0.11 USD, resulting in a -78.25% surprise. Revenue reached 390.00 ألف, compared to an expected --, with a 0.00% difference. The market reacted with a -16.11% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 4 المحللين forecast an EPS of -0.09 USD, with revenue projected to reach 3.07 مليون USD, implying an نقصان of -55.00% EPS, and زيادة of 685.92% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
٢٦ ديسمبر ٢٠٢٥ إلى ربع سنوي4 25
تقدير
-$0.49
الفعلي
-
مفاجئة
-
الأسئلة الشائعة
For Q3 2025, Iterum Therapeutics plc Ordinary Share reported EPS of -$0.20, missing estimates by -78.25%, and revenue of $390.00K, 0% as expectations.
The stock price moved down -16.11%, changed from $0.56 before the earnings release to $0.47 the day after.
The next earning report is scheduled for ٠٥ فبراير ٢٠٢٦.
Based on 4 المحللين, Iterum Therapeutics plc Ordinary Share is expected to report EPS of -$0.09 and revenue of $3.07M for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان